High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is an open label Phase I-II study to determine the safe doses of bortezomib,
sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in
improving survival.